Stock Scorecard



Stock Summary for Genprex Inc (GNPX) - $0.82 as of 5/22/2026 11:48:43 PM EST

Total Score

14 out of 30

Safety Score

19 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for GNPX

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for GNPX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for GNPX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for GNPX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for GNPX (19 out of 100)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 10
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for GNPX

Genprex, Inc. Announces Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting 5/26/2026 2:09:00 PM
Biomarker data link Trop-2 to PFS in Genprex (NASDAQ: GNPX) trials 5/26/2026 12:09:00 PM
Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting 5/26/2026 12:09:00 PM
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting 5/16/2026 7:40:00 AM
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting 5/15/2026 5:09:00 AM
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting 5/14/2026 4:39:00 PM
Genprex, Inc. Files Form 8-K With SEC – Company Information and Filing Details for May 14, 2026 5/14/2026 3:41:00 PM
Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT 5/14/2026 12:09:00 PM
Genprex Announces Positive Preclinical Data for Diabetes Gene Therapy 5/14/2026 12:09:00 PM
Gene therapy reversed high blood sugar in type 2 diabetic mice in 4 weeks 5/14/2026 12:09:00 PM

Financial Details for GNPX

Company Overview

Ticker GNPX
Company Name Genprex Inc
Country N/A
Description Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 3/31/2026
Next Earnings Date N/A

Stock Price History

Last Day Price 0.82
Price 4 Years Ago 2,900.00
Last Day Price Updated 5/22/2026 11:48:43 PM EST
Last Day Volume 238,684
Average Daily Volume 937,254
52-Week High 55.00
52-Week Low 0.74
Last Price to 52 Week Low 10.81%

Valuation Measures

Trailing PE N/A
Industry PE 108.94
Sector PE 66.00
5-Year Average PE -2,483.53
Free Cash Flow Ratio 0.48
Industry Free Cash Flow Ratio 25.30
Sector Free Cash Flow Ratio 34.59
Current Ratio Most Recent Quarter 5.61
Total Cash Per Share 1.70
Book Value Per Share Most Recent Quarter 2.42
Price to Book Ratio 0.49
Industry Price to Book Ratio 15.24
Sector Price to Book Ratio 23.00
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 13.16
Sector Price to Sales Ratio Twelve Trailing Months 5.25
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 10,586,400
Market Capitalization 8,680,848
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 23.13%
Reported EPS 12 Trailing Months -5.06
Reported EPS Past Year -14.88
Reported EPS Prior Year -8.34
Net Income Twelve Trailing Months -16,228,953
Net Income Past Year -16,228,953
Net Income Prior Year -21,111,163
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 18,049,255
Total Cash Past Year 7,830,855
Total Cash Prior Year 1,601,660
Net Cash Position Most Recent Quarter 18,049,255
Net Cash Position Past Year 7,830,855
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 7,961,876
Total Stockholder Equity Prior Year 1,620,155
Total Stockholder Equity Most Recent Quarter 16,930,270

Free Cash Flow

Free Cash Flow Twelve Trailing Months -14,288,261
Free Cash Flow Per Share Twelve Trailing Months -1.35
Free Cash Flow Past Year -15,311,209
Free Cash Flow Prior Year -17,149,088

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.12
MACD Signal -0.14
20-Day Bollinger Lower Band 0.31
20-Day Bollinger Middle Band 1.67
20-Day Bollinger Upper Band 3.02
Beta -0.93
RSI 28.00
50-Day SMA 192.34
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 5/27/2026 11:57:21 PM EST